Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Recommendation of "Reduce" from Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) have earned an average rating of "Reduce" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $18.63.

Several equities research analysts have recently weighed in on IART shares. Wells Fargo & Company decreased their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Finally, JMP Securities decreased their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Quadrant Capital Group LLC boosted its holdings in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd boosted its holdings in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares during the last quarter. CWM LLC boosted its holdings in Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after purchasing an additional 5,367 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Integra LifeSciences during the first quarter worth about $223,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Trading Up 2.0%

Shares of NASDAQ IART opened at $13.00 on Wednesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.72 and a current ratio of 1.21. Integra LifeSciences has a 52-week low of $11.06 and a 52-week high of $32.66. The firm has a 50 day moving average price of $13.02 and a two-hundred day moving average price of $18.87. The stock has a market cap of $1.01 billion, a P/E ratio of -34.21, a price-to-earnings-growth ratio of 0.71 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter last year, the company posted $0.55 earnings per share. The company's revenue was up 3.7% compared to the same quarter last year. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.